Prof dr hab. Tomasz Hermanowski

Education 

1988 - Habilitation in Economics, Main School of Commerce (SGH), Warsaw,
1974 - Doctor of Economics, Academy of Economics, Katowice,
1970 - Master of Economics, Main School of Commerce (SGH), Warsaw.
Area of Specialisation 

Application of marketing concepts to pharmaceutical policy formulation and strategic management in international business. Drug utilisation studies and pharmacoeconomics.
Academic Training 

Accounting, Economics, Statistics, Principles of Econometrics, Economic Policy and Planning, International Finance and Banking, Strategic Marketing (Harvard Business School), International Transfer of Technology (Massachusetts Institute of Technology), Comparative Economic Systems (Harvard University), Socio Economic Evaluation of Medicines (Centre for Health Economics, University of York).

1977-1978 - Senior Fulbright Scholar, Harvard University Center for International Affairs, 6 Divinity Avenue, Cambridge, Mass.02138. 
Professional Experience 

1996 - 1997 - Human Resources, Business Development & Communications Director, Rhone- Poulenc Rorer Sp. z o.o., Warsaw, Poland
1994 - 1996 - Country Manager, Fisons Pharmaceuticals Sp.z o.o., Warsaw
1993 - 1994 - General Manager, Cilag Division of Johnson & Johnson, Warsaw
1989 - 1993 - General Manager, Sandoz Pharma Services Ltd., Branch Office in Warsaw 
Academic Experience 

2002 - Warsaw University of Technology Business School, Professor of Marketing, supervising post-graduate Advanced Management Training Program in Pharmacoeconomics, Pharmaceutical Law and Marketing,
2005 - Medical University of Warsaw, Faculty of Pharmacy, Head of Pharmaceutical Care R&D Center 
Publications 

1. In foreign countries:

1.1. Spławiński J., Kuźniar J., Mazurek A.P., Hermanowski T., Recommendations for reimbursement based on .Added Health Value. and the concept of .Paneuropean Perfect List of Reimbursement., SIAR NEWS, April 2000, Pavia, Italy,

2. In Poland:

2.1. Hermanowski T., Strategie zewnętrznego zasilania krajowych procesów innowacyjnych, Katowice, 1986, Akademia Ekonomiczna im.Karola Adamieckiego w Katowicach,
2.2. Hermanowski T., Jaworski R., Czech M., Pachocki R., Ekonomiczne konsekwencje występowania nadciśnienia tętniczego w Polsce-doniesienia wstępne (Economic Consequences of Hypertension in Poland), Postępy Farmakoterapii, Vol.2, No 1 / 2, March/June 2001, p.30,
2.3. Hermanowski T., Spławiński J., Groyecki K., Nowicki D., Wpływ polityki lekowej na dostępność leków oraz finanse publicznej ochrony zdrowia (The Impact of Drug Policy on Availability of Drugs and Public Health Service Finances), Zdrowie i Zarządzanie, Vol. III, No. 6/2001, p.89,
2.4. Hermanowski T., Jaworski R., Czech M., Pachocki R., Ocena kosztów związanych z występowaniem nadciśnienia tętniczego w Polsce (Estimation of Hypertension Costs in Poland), Nadciśnienie Tętnicze, 2001, Vol. 5, No.2, p.83.
2.5. Hermanowski T., Jaworski R., Czech M., Pachocki R., Ocena kosztów i efektów leczenia hipotensyjnego przy użyciu dwóch różnych inhibitorów konwertazy angiotensyny : peryndoprylu i enalaprylu (Evaluation of Costs and Effects of Antihypertensive Treatment with Two Different Angiotensine Converting Enzyme Inhibitors: Perindopril and Enalapril) , Farmakoeonomika, 2001, No. 4, p.2-12
2.6. Hermanowski T., Jaworski R., Czech M., Pachocki R., Od globalnej oceny kosztów choroby do oceny opłacalności leczenia - strategia oceny farmakoekonomicznej w Polsce na przykładzie nadciśnienia tętniczego (From Evaluation of Global Disease Burden to Evaluation of Treatment Effectiveness . Pharmacoeconomic Evaluation Strategy in Poland . the Hypertension example), Kardiologia Po Dyplomie, June 2002, p .14-18
2.7. Hermanowski T., Jaworski R., Czech M., Pachocki R., Ocena kosztów związanych z występowaniem i leczeniem nadciśnienia tętniczego w Polsce z punktu widzenia płatnika i społeczeństwa (Estimation of Hypertension Disease and Treatment Costs in Poland, from the society.s and payor.s point of view), II Konferencja Naukowa Polskiego Towarzystwa Farmakoekonomicznego, Warszawa, 27 kwietnia 2004 (Second Scientific Conference of the Polish Society for Pharmacoeconomics, Warsaw, April 27, 2004)
2.8. Hermanowski T., Tytko Z., PBM . czy Polska może skorzystać ze sprawdzonych wzorów? (PBM . may Poland benefit from proven models?), Menedżer Zdrowia, No.1/February-March 2005, p.46-52

3. Lectures, Posters and Presentations at International Conferences;

3.1. International Society for Pharmacoeconomics and Outcomes Research, 5th Annual International Meeting, May 21-24, 2000, Arlington, Virginia, USA, Kuźniar J., Orlewska E., Hermanowski T., Romańczuk W., Spławiński J., Cost-effectiveness of Prevention of Coronary Heart Disease (CHD) with Simwastatin in Poland, Contributed Podium Presentation,
3.2. ISPOR (International Society for Pharmacoeconomics and Outcomes Research), Fourth Annual European Congress, 11-13 November 2001, Cannes, France; Hermanowski T., Jaworski R., Czech M., Pachocki R., Costs of Hypertension in Poland, poster.
3.3. Pharma in Poland 2002, EF International Conference, Warszawa, June 17 . 18, 2002, Hermanowski T., The Impact of Pharmacy Benefit Management Services on Marketing of Pharmaceuticals, lecture
3.4. ISPOR (International Society for Pharmacoeconomics and Outcomes Research), Fifth Annual European Congress, 2 - 5 November 2002, Rotterdam, The Netherlands; Hermanowski T., Jaworski R., Czech M., Pachocki R., Pharmacoeconomic Comparison of Antihypertensive Treatment with Two Different Angiotensine Converting Enzyme Inhibitors: Perindopril and Enalapril, Contributed Poster Presentation
3.5. ISPOR (International Society for Pharmacoeconomics and Outcomes Research), Fifth Annual European Congress, 2 - 5 November 2002, Rotterdam, The Netherlands; Hermanowski T., Czech M., Spławiński J., What is the Willingness to Pay for Future Health Benefits among Hypertensive Patients . a Pilot Study in Polish Setting, Contributed Poster Presentation
3.6. ISPOR (International Society for Pharmacoeconomics and Outcomes Research), Sixth Annual European Congress, 9-11 November 2003, Barcelona, Spain; Hermanowski T., Advanced Management Training Program in Pharmacoeconomics, Pharma Marketing and Law, Presentation
3.7. ISPOR (International Society for Pharmacoeconomics and Outcomes Research), Seventh Annual European Congress, 24-26 October 2004, Hamburg, Germany; Hermanowski T., Jaworski R., Czech M., Pachocki R., Costs of Hypertension in the Elderly in Comparison with Patients under 65 in Poland, Contributed Poster Presentation
3.8. ISPOR (International Society for Pharmacoeconomics and Outcomes Research), Seventh Annual European Congress, 24-26 October 2004, Hamburg, Germany; Hermanowski T., Jaworski R., Czech M., Pachocki R., Cost effectiveness of Antihypertensive Mono-Therapy with Peridnopril or Enalapril in Elderly Patients from the Third Party Payer Perspective, Contributed Poster Presentation
3.9. ISPOR (International Society for Pharmacoeconomics and Outcomes Research), Seventh Annual European Congress, 24-26 October 2004, Hamburg, Germany; Hermanowski T., Jaworski R., Czech M., Pachocki R., Costs of Hypertension in Poland from the Third Party Payer Perspective in Comparison with the Societal Perspective, Contributed Poster Presentation
3.10. ISPOR (International Society for Pharmacoeconomics and Outcomes Research), 8th Annual European Congress, 6-8 November 2005, Florence , Italy; Hermanowski T., Jaworski R., Czech M., Pachocki R., Evaluation of Costs Related to Hypertension in Patients with Uncontrolled Hypertension in Poland, Contributed Poster Presentation
3.11. ISPOR (International Society for Pharmacoeconomics and Outcomes Research), 8th Annual European Congress, 6-8 November 2005, Florence , Italy; Hermanowski T., Jaworski R., Czech M., Pachocki R., Evaluation of Costs Related to Hypertension in Patients with Concomitant Diseases in Poland, Contributed Poster Presentation 
Scientific Committees 

2005 - Chair, ISPOR Educator.s Tool-Kit Task Force 
Public Service 

2004 . 2006 President-Elect, Polish Society for Pharmacoeconomics 
Personal Data

Born Feb.29, 1948, Gliwice, Poland.